GLP-1 Receptor Agonist Market Analysis

GLP-1 Receptor Agonist Market Analysis

To get key market trends

  Download Free Sample

Based on drug class, the global industry is subdivided into semaglutide, dulaglutide, liraglutide, exenatide, and other drug classes. The semaglutide segment dominated the global GLP-1 receptor agonist market in 2022. It is a class of drugs indicated for improving glycemic control in adults with type-2 diabetes mellitus as an adjunct to diet and exercise and used for treating obesity. It is also indicated for adults with type 2 diabetes to reduce the risk of major cardiovascular events. Along with this, the increasing prevalence of diabetes and obesity increases the demand for semaglutide, leading to the growth of this market.
 

Based on route of administration, the GLP-1 receptor agonist market is subdivided into parenteral and oral routes of administration. The parenteral segment held the highest market share in 2022 owing to the advantages offered such as immediate onset of action, better bioavailability, easy absorption of active form of medications and zero chances of interference. Many of the GLP-1 receptor agonist drugs are administered by parenteral routes; for instance, Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Exenatide (Bydureon, Byetta) are available in injections form.
 

Based on application, the global GLP-1 receptor agonist market is classified into type 2 diabetes mellitus, obesity, and other applications. The type 2 diabetes mellitus segment accounted for the largest share in 2022. The GLP-1 receptor agonist plays an important role in stimulating release of insulin and suppressing glucagon secretion when the blood glucose levels are high. They help in treating type 2 diabetes patients and promote weight loss. Factors such as the increasing prevalence of type 2 diabetes, growing demand for treatment, and increased prescriptions of GLP-1 receptor agonist drugs are contributing to the growth of this segment.
 

Based on distribution channel, the global GLP-1 receptor agonist market is subdivided into hospital, retail, and online pharmacies. Among the distribution channel segments, the hospital segment held the highest revenue share of the market in 2022. The large share of this segment can be attributed to the large patient pool towards hospital, wide availability of medicines in hospital pharmacies, and continuous availability of diabetes consultant in the hospitals.
 

Furthermore, the increasing prevalence of chronic diseases, development of new therapies for type 2 diabetes, increasing government initiatives in launching the new drugs, and need for long term treatment of chronic diseases like diabetes and obesity are expected to drive the growth of this segment.
 

Based on region, global GLP-1 receptor agonist market is subdivided into North America, Europe, Asia Pacific, Latin America, and the Middle East, and Africa. In 2022, the North America held the highest revenue in this market, owing to high prevalence of chronic diseases such as diabetes and obesity, increasing investments for R&D for developing new drugs for treating diabetes and obesity, presence of key players, and well-developed healthcare infrastructure in the region. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the increasing prevalence of chronic diseases and increased government initiatives and fundings for diagnosis and treatment of diabetes.
 

In North America segment, the U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for GLP-1 receptor agonist products.